8-K: Evofem Amends Merger Pact, Issues New Convertible Preferred Stock

Evofem Biosciences has amended its merger agreement with Aditxt for the sixth time and issued new Series G-1 Convertible Preferred Stock by exchanging $1.573 million in senior secured convertible notes.

Summary

• The Company, Aditxt, Inc., and Adifem, Inc. entered into the Sixth Amendment to the Amended and Restated Merger Agreement on August 26, 2025.
• The Sixth Amendment updates the definition of 'Unconverted Company Preferred Stock' to include Series G-1 Convertible Preferred Stock and clarifies 'Company Shareholder Approval' to include all voting preferred stock.
• The amendment also specifies that the Company will assist in obtaining Exchange Agreements for convertible noteholders to exchange notes and purchase rights for an aggregate of not more than 89,021 shares of Parent Preferred Stock.
• The maximum number of dissenting shares was adjusted to 5,932,818 shares of Common Stock or 202 shares of Preferred Stock.
• A new requirement was added for waivers from holders of the Company's E-1 Convertible Preferred Stock regarding specific provisions of their Certificate of Designations.
• On August 22, 2025, the Company exchanged senior secured convertible notes totaling $1,573,000 for 1,573 shares of newly created Series G-1 Convertible Preferred Stock.
• The Series G-1 Preferred Stock has a stated value of $1,000 per share and is convertible into Common Stock at a conversion price of $0.0154 per share, subject to adjustment.
• Holders of Series G-1 Preferred Stock are entitled to vote with common shareholders and receive monthly dividends at an 8% annual rate, payable in Common Stock or as paid-in-kind (PIK) additional Series G-1 Preferred Stock.
• The Series G-1 Preferred Stock terms include 'Triggering Events' (e.g., failure to deliver shares, trading suspension, bankruptcy, judgments over $100,000) that can lead to an 'Alternate Conversion Price' (as low as 80% of VWAP) and an increased dividend rate of 12% per annum.
• Upon a 'Bankruptcy Triggering Event,' the Company is required to immediately redeem outstanding Series G-1 Preferred Stock in cash at a premium.

Sentiment

Score: 4

Explanation: The conversion of debt to preferred stock is a positive for balance sheet health, but the numerous amendments to the merger agreement and the potentially highly dilutive terms of the new preferred stock (Alternate Conversion Price, high default dividend rate, extensive Triggering Events) introduce significant risks and suggest underlying challenges. The overall sentiment is cautious due to these complexities and potential future dilution.

Positives

• The conversion of $1,573,000 in senior secured convertible notes into Series G-1 Convertible Preferred Stock reduces the Company's outstanding debt obligations, potentially improving its balance sheet.
• The option to pay dividends on the Series G-1 Preferred Stock as paid-in-kind (PIK) additional shares provides the Company with flexibility in managing its cash flow by deferring cash dividend payments.

Negatives

• The Sixth Amendment to the merger agreement indicates ongoing complexities and potential delays in the merger process, as this is the sixth amendment since July 2024.
• The Series G-1 Preferred Stock includes 'Triggering Events' that, if activated, allow holders to convert at a significantly discounted 'Alternate Conversion Price' (as low as 80% of VWAP), potentially leading to substantial dilution for common shareholders.
• The dividend rate for Series G-1 Preferred Stock automatically increases from 8% to 12% per annum upon the occurrence and continuance of a Triggering Event, increasing the cost of capital under adverse conditions.
• The beneficial ownership limitation of 19.99% for Series G-1 Preferred Stock conversions could restrict large-scale conversions, potentially impacting liquidity for holders.

Risks

• Merger Completion Risk: The ongoing amendments to the merger agreement suggest potential difficulties or changes in terms, raising uncertainty about the ultimate completion of the merger with Aditxt.
• Dilution Risk: The Series G-1 Preferred Stock is convertible into common stock, and the 'Alternate Conversion Price' mechanism, triggered by various adverse events, could lead to significant dilution for existing common shareholders if conversions occur at a substantial discount to the market price.
• Financial Distress Risk (Triggering Events): A wide range of 'Triggering Events' (e.g., failure to deliver common stock upon conversion, trading suspension, failure to pay dividends, bankruptcy, judgments over $100,000, breach of covenants, material adverse effect) could accelerate obligations, increase dividend rates, or force mandatory redemption at a premium, putting financial strain on the Company.
• Liquidity Risk: Failure to timely deliver common stock upon conversion of Series G-1 Preferred Stock can result in significant cash penalties (liquidated damages of $50-$200 per business day per $1,000 of stated value) and 'Buy-In' costs, impacting the Company's liquidity.
• Corporate Governance Risk: The requirement for waivers from E-1 Convertible Preferred Stock holders for certain provisions suggests potential conflicts or complexities in managing different classes of preferred stock and their rights.
• Regulatory Compliance Risk: Failure to comply with Principal Market listing rules regarding the issuance of common stock upon conversion (Exchange Cap) could require stockholder approval or lead to non-compliance.

Future Outlook

The Company intends to file a proxy statement in connection with the proposed merger with Aditxt, Inc., which will contain important information for stockholders regarding the merger and related matters. Stockholders will need to vote on the proposed merger.

Industry Context

The amendment to the merger agreement and the debt-to-equity conversion reflect ongoing strategic adjustments within the biotechnology or pharmaceutical sector, particularly for companies navigating complex M&A processes and managing capital structure. The conversion of debt to preferred stock can be a mechanism to strengthen the balance sheet and reduce immediate cash burdens, common in growth-stage or financially constrained companies in the industry. The detailed 'Triggering Events' and 'Alternate Conversion Price' mechanisms are typical features in high-risk, high-reward financing for companies in this sector, often indicating a need for capital preservation and investor protection in volatile market conditions.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for significant dilution due to the conversion features of the Series G-1 Preferred Stock, especially if 'Triggering Events' lead to conversions at the 'Alternate Conversion Price'. The requirement for shareholder approval for the merger gives them a voice in the strategic direction.
• Preferred Stock Holders (Series G-1): Benefit from strong anti-dilution protections, a fixed dividend rate (8%, increasing to 12% on default), and robust remedies upon 'Triggering Events', including mandatory redemption at a premium or conversion at a discounted price. This provides a high level of security and potential upside.
• Convertible Noteholders: Those who exchanged their notes for Series G-1 Preferred Stock converted debt into equity, potentially reducing immediate credit risk but shifting their investment to a different class of security with new terms. Other noteholders may exchange for Parent Preferred Stock as part of the merger.
• Aditxt, Inc. (Acquirer): The amendments to the merger agreement indicate ongoing negotiations and adjustments to the acquisition terms, which could affect the final cost or structure of the deal. The waivers from E-1 Preferred Stock holders are crucial for the merger's smooth execution.

Next Steps

• The Company intends to file a proxy statement for the proposed merger.
• Stockholders of the Company will need to vote on the proposed merger.
• The Company will assist in obtaining Exchange Agreements from Company convertible noteholders for Parent Preferred Stock.
• The Company must ensure compliance with the terms of the Series G-1 Preferred Stock, including dividend payments and conversion mechanics, to avoid Triggering Events.

Key Dates

Recommendation

The filing presents a mixed bag of developments. While the conversion of debt to preferred stock can be seen as a positive step in managing the Company's balance sheet and reducing immediate cash outflows, the repeated amendments to the merger agreement with Aditxt suggest ongoing complexities and uncertainties surrounding the acquisition. The terms of the newly issued Series G-1 Convertible Preferred Stock, particularly the 'Alternate Conversion Price' mechanism and the extensive list of 'Triggering Events,' introduce significant potential for future dilution for common shareholders. The increased dividend rate upon a Triggering Event also adds to the cost of capital under adverse conditions. Given the continued uncertainty around the merger's final terms and the potential for substantial dilution, a 'hold' recommendation is appropriate. Investors should monitor the progress of the merger, the Company's financial performance, and any further capital structure changes closely before making new investment decisions.

Keywords

Evofem Biosciences, Aditxt, Merger Agreement, Series G-1 Preferred Stock, Convertible Notes, Debt Exchange, Corporate Governance, SEC Filing, 8-K, Preferred Stock, Dilution, Triggering Events, Capital Restructuring, Corporate Merger